Jonathan Burlison, PhD
Patient Safety Project manager
Jonathan Burlison, Ph.D., is the Patient Safety Project manager in the Pharmaceutical Sciences Department at St. Jude Children’s Research Hospital.
Stories by Jonathan Burlison
Learn the basics of CAR T-cell therapy and how it is being used in the SJCAR19 clinical trial at St. Jude
Learn the basics of CAR T-cell immunotherapy and how it is being used in the SJCAR19 clinical trial for acute lymphoblastic leukemia.
Managing pain without enabling opioid addiction
How do physicians manage their patients’ pain in the context of the current opioid crises? Read how this physician helped a patient.
A moving target: Taking aim at the shift and drift of influenza viruses
How close are we to a flu pandemic? Read how it could happen and what researchers are doing to prevent it.
Blazing through new territory to fight a devastating neurodegenerative disease
Read how researchers have found a path to control coenzyme A and possibly prevent a devastating neurodegenerative disease.
Why I strive to be like my mentor
Read how mentoring transformed a small-town college student into an epidemiologist.
Postdoc survival guide: On the road to big discovery, you’re allowed to stumble on your first steps
New lab, new investigators, new personalities, new team – learn how to make it in your first year as a postdoc.
Can obesity give influenza more time to spread and make vaccines less effective?
St. Jude researchers, led by Dr. Stacey Schultz-Cherry, are asking questions about potential association between flu severity and the obesity epidemic.
Gut microbiome sequencing opens new possibilities for predicting infection in leukemia patients
Researchers identify intestinal microbiota that may predict infection risk during chemotherapy in pediatric ALL patients. Learn about the gut microbiome.
New drug for a rare disorder: How will Gamifant’s approval affect HLH treatment?
HLH, a rare disorder of the immune system, is caused by a buildup of proteins responding to infection. Read about a new treatment that limits that buildup.
Tumor microenvironment switches from homely to hostile when this process is turned off
Researchers learn how this housekeeper for cancer cells turns into a cancer house killer. Learn how targeting LAP could promote an anti-tumor response and slow tumor growth.